CliffBio
biologic

Dupixent

dupilumab

Loss of exclusivityJune 2032projected — 12-year biologic exclusivity estimate
CompanyRegeneron Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameDupixent
Active ingredientdupilumab
Strength300MG/2ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2020
Marketing statusRx

More from Regeneron Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Dupixent patent cliff — loss of exclusivity June 2032 | CliffBio